ATE268813T1 - Vektoren der alphavirus cdna - Google Patents

Vektoren der alphavirus cdna

Info

Publication number
ATE268813T1
ATE268813T1 AT95914666T AT95914666T ATE268813T1 AT E268813 T1 ATE268813 T1 AT E268813T1 AT 95914666 T AT95914666 T AT 95914666T AT 95914666 T AT95914666 T AT 95914666T AT E268813 T1 ATE268813 T1 AT E268813T1
Authority
AT
Austria
Prior art keywords
present
cdna
polynucleotide molecules
animal
desired products
Prior art date
Application number
AT95914666T
Other languages
English (en)
Inventor
Peter Liljestroem
Henrik Garoff
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE268813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Application granted granted Critical
Publication of ATE268813T1 publication Critical patent/ATE268813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
AT95914666T 1994-03-31 1995-03-30 Vektoren der alphavirus cdna ATE268813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors
PCT/SE1995/000343 WO1995027044A1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS

Publications (1)

Publication Number Publication Date
ATE268813T1 true ATE268813T1 (de) 2004-06-15

Family

ID=20393495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914666T ATE268813T1 (de) 1994-03-31 1995-03-30 Vektoren der alphavirus cdna

Country Status (12)

Country Link
US (1) US6566093B1 (de)
EP (1) EP0753053B1 (de)
JP (1) JPH09511143A (de)
AT (1) ATE268813T1 (de)
AU (1) AU699384B2 (de)
CA (1) CA2184261A1 (de)
DE (1) DE69533130T2 (de)
DK (1) DK0753053T3 (de)
ES (1) ES2223051T3 (de)
FI (1) FI963860A7 (de)
SE (1) SE9401091D0 (de)
WO (1) WO1995027044A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
EP0981636B1 (de) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Auf lentivirus basierende gentransfer-vektoren
FI110323B (fi) 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
ES2268797T3 (es) * 1997-11-14 2007-03-16 Sanofi Pasteur Limited Vectores alvirus.
EP1707633A1 (de) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus
CA2309826A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
EP1261638A2 (de) 2000-03-08 2002-12-04 Chiron Corporation Humanes fgf-23 gen und genexpressionsprodukte
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
JP5089847B2 (ja) * 2001-03-27 2012-12-05 ニューヨーク・ユニバーシティ アルファウイルスに基づく高親和性ラミニン受容体標的化ベクターを用いた腫瘍の治療
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
JP5079981B2 (ja) 2002-12-13 2012-11-21 アルファバックス，インコーポレイティド アルファウイルス粒子及び調製方法
EP1585812B1 (de) 2002-12-13 2017-01-18 Alphavax, Inc. Multiantigene alphavirusrepliconpartikel und verfahren
KR101518309B1 (ko) 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
EP1651666B1 (de) 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
ES2292271B1 (es) 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
WO2007046839A2 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
KR20110044836A (ko) * 2008-05-23 2011-05-02 핏 바이오테크 오와이 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도
CL2008002322A1 (es) * 2008-08-07 2009-06-05 Univ Concepcion Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
CN115197964A (zh) * 2021-04-12 2022-10-18 华南农业大学 一种改进型pSFV1载体及其制备方法与应用
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
EP0711829A3 (de) 1993-09-15 1997-07-09 Viagene Inc Rekombinanter Alphavirus Vektor
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems

Also Published As

Publication number Publication date
EP0753053B1 (de) 2004-06-09
DE69533130T2 (de) 2005-07-07
ES2223051T3 (es) 2005-02-16
FI963860A0 (fi) 1996-09-27
DE69533130D1 (de) 2004-07-15
WO1995027044A1 (en) 1995-10-12
JPH09511143A (ja) 1997-11-11
SE9401091D0 (sv) 1994-03-31
CA2184261A1 (en) 1995-10-12
US6566093B1 (en) 2003-05-20
AU699384B2 (en) 1998-12-03
AU2155795A (en) 1995-10-23
FI963860A7 (fi) 1996-09-27
DK0753053T3 (da) 2004-10-11
EP0753053A1 (de) 1997-01-15

Similar Documents

Publication Publication Date Title
DE69533130D1 (de) VEKTOREN DER ALPHAVIRUS cDNA
IT7927940A0 (it) Estrattore chirurgico per asportare corpi estranei che si trovano nelle vie naturali del corpo umano, come calcoli e simili.
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69535376D1 (de) Expressionsvektor des alphavirus
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
EP0365598A4 (en) Therapeutic antimicrobial polypeptides, their use and methods for preparation
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ATE230985T1 (de) Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
FI844510L (fi) Ensym-resistenta immunsystemet modulerande peptider.
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE98652T1 (de) Chemische derivate von ghl-cu.
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TW200407425A (en) Human coagulation factor VII polypeptides
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
BR0213121A (pt) modelo in vitro para atividade priocidal
GB2030043B (en) Injectable composition for the treatment of helminthiasis and clostridial diseases in animals
DK0556395T3 (da) Hidtil unkendt cytokin
ATE139702T1 (de) Die freisetzung des histamin hemmenden faktors sowie diesen enthaltende präparate
EP0691347A4 (de) Wachstumssubstanz für leberparenchymzellen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0753053

Country of ref document: EP